{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:46:43Z","timestamp":1782326803143,"version":"3.54.5"},"reference-count":24,"publisher":"Academy of Managed Care Pharmacy","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.18553\/jmcp.2026.32.7.773","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:52:53Z","timestamp":1782323573000},"page":"773-781","source":"Crossref","is-referenced-by-count":0,"title":["US commercial health plan use of corticosteroids in step therapy protocols: Frequency and clinical appropriateness"],"prefix":"10.18553","volume":"32","author":[{"given":"Yichen","family":"Lin","sequence":"first","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shi","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Beinfeld","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Campbell","sequence":"additional","affiliation":[{"name":"argenx, Inc, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chambers","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"key":"r1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2017.1553"},{"key":"r2","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2024.01484"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2021.00822"},{"key":"r4","volume-title":"StatPearls","author":"Hodgens A","year":"2025"},{"key":"r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2010.04.005"},{"key":"r6","unstructured":"sanofi-aventis US LLC. KEVZARA\n                      \u00ae\n                      (sarilumab) [package insert]. US Food and Drug Administration website. Published online June 2024. Accessed August 1, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761037s015lbl.pdf"},{"key":"r7","volume-title":"StatPearls","author":"Yasir M","year":"2023"},{"issue":"2","key":"r8","first-page":"203","volume":"14","author":"Ericson-Neilsen W","year":"2014","journal-title":"Ochsner J"},{"key":"r9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00703-2018"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011"},{"key":"r11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201904-0903SO"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2477877"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2016.1233101"},{"key":"r14","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.2.141"},{"key":"r15","unstructured":"National Association of Insurance Commissioners.\n                      2023 Accident and Health Policy Experience Report\n                      . National Association of Insurance Commissioners; 2024. Accessed XX. https:\/\/content.naic.org\/sites\/default\/files\/publication-ahp-lr-accident-health-report.pdf"},{"key":"r16","unstructured":"Janssen Biotech, Inc. REMICADE\n                      \u00ae\n                      (infliximab) [package insert]. US Food and Drug Administration website. 2025. Accessed August 19, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/103772s5412lbl.pdf"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.04.010"},{"key":"r18","unstructured":"Genentech, Inc. XOLAIR\n                      \u00ae\n                      (omalizumab) [package insert]. US Food and Drug Administration website. Published online February 2024. Accessed August 2, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/103976s5245lbl.pdf"},{"key":"r19","volume-title":"StatPearls","author":"Lam C","year":"2025"},{"key":"r20","unstructured":"Medical Guideline Clearinghouse and Library. Guidelines. Guideline Central. Accessed July 25, 2025. https:\/\/www.guidelinecentral.com\/guidelines"},{"key":"r21","unstructured":"UpToDate. UpToDate: trusted, evidence-based solutions for modern healthcare. Wolters Kluwer. Accessed July 25, 2025. https:\/\/www.wolterskluwer.com\/en\/solutions\/uptodate"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"r23","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001153"},{"key":"r24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2117582"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:53:11Z","timestamp":1782323591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.7.773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.18553\/jmcp.2026.32.7.773"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.7.773","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}